SCYNEXIS, Inc. Expense Related to Distribution or Servicing and Underwriting Fees
SCYNEXIS, Inc. (SCYX) had Expense Related to Distribution or Servicing and Underwriting Fees of $3.30 million as of 2014-05-07, per its 10-K filed 2018-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees · last filed 2018-03-13
- 2014-05-07: Expense Related to Distribution or Servicing and Underwriting Fees $3.30M; Expense Related to Distribution or Servicing and Underwriting Fees as first filed $3.29M.
| Period end | Expense Related to Distribution or Servicing and Underwriting Fees | Expense Related to Distribution or Servicing and Underwriting Fees as first filed |
|---|---|---|
| 2014-05-07 | $3.30M 10-K · filed 2018-03-13 | $3.29M 10-Q · filed 2014-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |